Study of C5252 for people with recurrent high-grade glioma
Part of Cancer clinical trials.
This trial tests a new medicine called C5252 for people whose high-grade glioma (a type of brain tumor) has come back after standard treatment. The medicine is given directly into the brain through a small device placed under the scalp (Ommaya reservoir) after surgery to remove as much of the tumor as possible.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a recurrent high-grade glioma (a fast-growing brain tumor) that has not responded to standard therapies.
- You have at least one measurable tumor that can be seen on MRI scans.
- You have had surgery and there is enough room left in the tumor cavity for a 1 mL dose of the study drug.
- You have an Ommaya reservoir (a small device placed under your scalp) that can be used to give the drug into the brain.
- You are well enough to carry out daily activities (Karnofsky score of 60% or higher) and expected to live more than 12 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests a new brain-tumor treatment in people with recurrent (coming back) high-grade glioma (brain cancer). The study uses injected medicine along with an implanted tumor device and aims to find whether the treatment is safe and can shrink or control tumors.
This Phase 2 study tests ERC1671 together with four other medicines to treat recurrent or worsening glioblastoma (a WHO grade IV brain cancer). It aims to slow tumor growth and improve outcomes after the tumor comes back.
This trial tests a new drug, GC001, injected directly into the tumor in people with high-grade gliomas (WHO grade 3 or 4) that have come back or are growing. It may be an option if standard treatments have stopped working.
This trial tests a new drug called BioTTT001 for people whose high-grade brain tumor has come back after standard treatment. The drug is given through a small device placed in the head to deliver it directly to the tumor area.
This trial tests a new treatment combining an oncolytic virus with a PD-1 inhibitor for people whose high-grade glioma has come back after standard therapy. The virus is injected directly into the tumor through a device placed in the head, and the drug helps your immune system fight the cancer cells.
This study tests a laser ablation treatment for people whose high-grade glioma (a fast-growing brain tumor) has come back after standard therapy. The goal is to see if this minimally invasive laser procedure can help control the tumor.
Hear when a new Glioma, Malignant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.